Stephen Shrewsbury

Chief Medical Officer

Stephen joined Impel in March 2017. Prior to that, Dr. Shrewsbury was the Executive Vice President, Development, and Chief Medical Officer (CMO) at Fortuna Fix Inc., a clinical biotechnology company. Dr. Shrewsbury was the CMO and Senior Vice President, Clinical Development of Aquinox Pharmaceuticals Inc., a pharmaceutical company focused on treating inflammation, inflammatory pain, and blood cancers from 2013-2016. Prior to that, Dr. Shrewsbury served in executive positions (CMO) at various other pharmaceutical companies, including MAP Pharmaceuticals, Inc., AVI BioPharma, Inc. (now Sarepta Therapeutics) and Adamas Pharmaceuticals. During his time as Inhaled Antibiotic Core Team leader at Chiron Corporation, Stephen was on the International Pharmaceutical Aerosol Consortium Board of Science. He moved to the US during his 9 years with Glaxo, becoming medical lead for their Upper Respiratory Inflammatory Disorder team, after working in the UK’s NHS for20 years. Stephen holds an M.B. ChB. from the University of Liverpool, an MRCGP from the Royal College of General Practitioners and a Diploma in Pharmaceutical Medicine from the Royal College of Physicians.

Stephen-Shrewsberry